TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC

Background: Genetic mutations are quite common in non-small cell lung cancer (NSCLC), however, their prognostic value remains controversial. Methods: This study explored the mutational landscape of tumor samples from patients with advanced NSCLC by next-generation sequencing (NGS). A total of 101 NS...

Full description

Bibliographic Details
Main Authors: Huijing Feng, Huiru Xu, Xiuhuan Shi, Guobin Ding, Cihui Yan, Linhan Li, Zuoyi Jian, Xuejing Yang, Hongxia Guo, Feng Li, Junping Zhang, Xiubao Ren
Format: Article
Language:English
Published: IMR Press 2023-07-01
Series:Frontiers in Bioscience-Landmark
Subjects:
nsclc
tp53 mutation
pfs
targeted sequencing
first-line treatment
Online Access:https://www.imrpress.com/journal/FBL/28/7/10.31083/j.fbl2807147

Internet

https://www.imrpress.com/journal/FBL/28/7/10.31083/j.fbl2807147

Similar Items